New delivery system guides curcumin to Parkinson’s-affected brain cells
Engineered exosomes delivered curcumin to dopamine neurons in rat models
Written by |
- Engineered exosomes delivered curcumin to Parkinson's-affected brain cells in rats.
- The system bypassed the blood–brain barrier and was linked to protection of dopamine neurons.
- Treatment was associated with improved motor and cognitive function and reduced brain inflammation.
Small particles called exosomes may help deliver curcumin directly to dopamine-producing nerve cells damaged in Parkinson’s disease, a study in rats suggests. In laboratory and animal experiments, the targeted delivery helped protect these cells and was associated with improved outcomes, pointing to a potential precision-delivery strategy for future research.
The study, “Engineered extracellular vesicles-mediated curcumin delivery in brain microenvironment modulating lysosomes, mitochondria, and microglia reprogram for Parkinson’s disease therapy,” led by researchers at China Medical University Hospital (CMUH) in Taiwan, was published in the Journal of Nanobiotechnology.
Why dopamine-producing neurons are lost in Parkinson’s
Parkinson’s is caused by the gradual loss of dopaminergic neurons, the nerve cells responsible for producing dopamine. Dopamine plays a key role in controlling movement, and its loss contributes to both the motor and nonmotor symptoms of Parkinson’s.
Curcumin — the natural compound that gives turmeric its yellow color — is known for its antioxidant and anti-inflammatory properties. However, a small clinical study in adults with Parkinson’s disease found that a specialized formulation called nanomicelle curcumin was safe and well tolerated, but did not improve symptoms or quality of life.
One major challenge is that curcumin breaks down quickly in the body and struggles to cross the blood–brain barrier, a tightly regulated layer of cells that blocks most drugs from entering the brain. To address this, researchers at CMUH collaborated with Ever Supreme Bio Technology and Shine-On Biomedical to design a delivery system using engineered exosomes.
According to a university press release, the researchers described the approach as a “world-first, actively navigated brain-targeting exosome platform.” The engineered exosomes, also called extracellular vesicles, “actively identify and target dopaminergic neurons — effectively equipping therapeutic agents with a GPS-like navigation system that directs them to diseased brain regions.”
How engineered exosomes deliver curcumin to brain cells
Exosomes are tiny particles naturally released by cells that can transport molecules to other cells. In this study, researchers engineered exosomes from lab-grown human cells to carry antibody fragments that bind to the dopamine transporter, a protein found on the surface of dopamine-producing neurons. Curcumin was loaded into these engineered exosomes, allowing it to be delivered more directly to the neurons affected in Parkinson’s.
In cell-based models of Parkinson’s disease, neurons efficiently took up the curcumin-loaded exosomes. Treatment reduced the buildup of abnormal alpha-synuclein proteins — a hallmark of Parkinson’s — and increased levels of several proteins involved in protecting nerve cells, including DJ-1, tyrosine hydroxylase, and PARKIN.
In animal experiments using a rat model of Parkinson’s, treatment with curcumin-loaded exosomes was associated with improvements in motor coordination and cognitive performance compared with untreated or placebo-treated animals. The treatment also appeared to protect dopamine-producing neurons and reduce brain inflammation, in part by shifting microglia, the brain’s immune cells, toward a more repair-oriented state.
Targeted delivery reaches key brain regions in Parkinson’s rats
The researchers found that curcumin delivered through dopamine transporter-targeting exosomes reached brain regions commonly affected in Parkinson’s, including the substantia nigra and ventral tegmental area. These findings suggest the engineered exosomes delivered curcumin into the brain and enriched it in intended target regions in rats.
“Taken together, these findings highlight [DAT-engineered exosomes] as a targeted drug delivery platform with the potential to revolutionize [Parkinson’s] treatment through precise and efficient drug administration,” the researchers wrote.
The press release noted that regulatory changes in Taiwan allow conditional approval for certain regenerative treatments targeting serious diseases. According to the release, the combination of targeted delivery, cellular protection, and immune modulation positions exosome-based approaches as a potential avenue for future research in Parkinson’s and other neurodegenerative conditions.
